Key points are not available for this paper at this time.
Abstract Women with a pathogenic vari ant (mutation hereafter) in the BRCA1 or BRCA2 gene face the highest known lifetime risks of developing breast cancer. Notably, incidence rates increase rapidly in early adulthood but remain high even after age 60. Thus, understanding how exogenous (anti)hormones impact these risks is important for the safe clinical management of high-risk women, especially following early surgical menopause. In this session, I will review the current data on the role of tamoxifen chemoprevention, as well as the impact of oral contraceptives, hormone replacement therapy and fertility medication on breast cancer risk. Where possible, I will also discuss associations with ovarian cancer, given that managing BRCA-cancer risks is a balancing act, and present findings by gene mutation. Gaps in the literature and opportunities for further research will also be described. Our goal should be to maximize survival while optimizing health following risk-reducing salpingo-oophorectomy. Citation Format: J. Kotsopoulos. Cancer risk associated with exogenous hormone use in BRCA mutation carriers abstract. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr SS02-03.
Joanne Kotsopoulos (Thu,) studied this question.